The Cooper Companies, Inc. $COO Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp trimmed its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 76.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 69,786 shares of the medical device company’s stock after selling 226,916 shares during the quarter. Boston Trust Walden Corp’s holdings in Cooper Companies were worth $3,945,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of COO. BlackRock Inc. purchased a new stake in Cooper Companies during the second quarter worth $1,077,762,000. Generation Investment Management LLP purchased a new position in shares of Cooper Companies in the 2nd quarter valued at $356,304,000. Jupiter Topco LLC purchased a new position in shares of Cooper Companies in the 2nd quarter valued at $305,074,000. JANA Partners Management LP increased its holdings in shares of Cooper Companies by 0.5% in the 2nd quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock valued at $256,900,000 after acquiring an additional 17,322 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Cooper Companies by 3.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company’s stock worth $248,758,000 after purchasing an additional 103,044 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Insider Buying and Selling at Cooper Companies

In related news, Director Paul Keel bought 4,701 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were acquired at an average price of $53.18 per share, with a total value of $249,999.18. Following the completion of the acquisition, the director owned 4,701 shares in the company, valued at approximately $249,999.18. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence Kurzius purchased 10,000 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were bought at an average price of $53.91 per share, with a total value of $539,100.00. Following the purchase, the director directly owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. The trade was a 90.10% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 34,701 shares of company stock worth $1,880,039. 2.08% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Bank of America downgraded Cooper Companies from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $80.00 to $65.00 in a research report on Thursday, September 10th. Citigroup reiterated a “neutral” rating and issued a $60.00 target price (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. UBS Group decreased their price target on shares of Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a research report on Thursday, September 10th. Barclays upgraded shares of Cooper Companies to a “hold” rating in a report on Wednesday, October 7th. Finally, William Blair downgraded shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $68.60.

Cooper Companies Stock Performance

Shares of COO traded down $1.15 during mid-day trading on Friday, hitting $62.36. 2,059,749 shares of the company’s stock were exchanged, compared to its average volume of 3,311,420. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The firm has a market capitalization of $11.86 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.41 and a beta of 0.83. The business’s 50 day moving average is $59.20 and its two-hundred day moving average is $68.61. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts expect that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its board has approved a stock buyback program on Wednesday, September 9th that permits the company to repurchase $3 billion in outstanding shares. This repurchase authorization permits the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.